<p>A study led by researchers at <a href="https://umiamihealth.org/en/sylvester-comprehensive-cancer-center"><strong>Sylvester Comprehensive Cancer Center</strong></a> suggests that CAR-T immunotherapy remains a viable option for patients who have lymphoma that goes into remission before the cell therapy begins. Video available.</p>
Use of an antibody drug conjugate and a PD-1 inhibitor brings complementary mechanisms together while eliminating the most toxic agent that has been used in combinations to treat classic Hodgkin lymphoma (cHL).
Cell therapy appears safe and effective for l eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
The most common treatments come with significant cardiovascular risk, but study investigators suggest newer options might offer a more favorable risk profile.
Patients with advanced-stage classic Hodgkin lymphoma had a longer progression-free survival rate with Opdivo plus AVD, a chemotherapy regimen, compared with Adcetris plus AVD.